Prof Sana Al Sukhun speaks to ecancer about the latest in HER2-low breast cancer. She discusses the latest in HER2-low BC treatment with trastuzumab and the explores the survival outcomes.
Prof Al Sukhun also speaks about antibody-drug conjugates (ADCs) technologies for management of metastatic breast cancer.